About: Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.
Sector: Healthcare
Industry: Biotechnology
Latest price: $0.97 (-0.40%)
TVRD NASDAQ Tvardi Therapeutics, Inc.
Tvardi Therapeutics, Inc. share price
Atividade de preço de TVRD
Último preço
$ 0,970
Variação (24h)
-0,00 USD (0,40%)
Volume
33.23K
Volume (média 4 sem.)
-
Abertura
$ 1,02
Variação do dia
$ 0,97 - $ 1,07
Fechamento anterior
$ 0,97
Último negócio
23 Oct, 3:21 pm GMT+0
Atrasado
23 Oct, 3:21 pm GMT+0
TVRD price performance
Atrasado
23 Oct, 3:21 pm GMT+0
quote.marketSignals